|
US5652258A
(en)
*
|
1995-05-30 |
1997-07-29 |
Gliatech, Inc. |
2-(4-imidazoyl) cyclopropyl derivatives
|
|
US6008240A
(en)
*
|
1997-12-15 |
1999-12-28 |
Gliatech, Inc. |
2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
|
|
WO2000042023A1
(en)
|
1999-01-18 |
2000-07-20 |
Novo Nordisk A/S |
Substituted imidazoles, their preparation and use
|
|
US7265115B2
(en)
|
1999-01-29 |
2007-09-04 |
Abbott Laboratories |
Diazabicyclic CNS active agents
|
|
US6908926B1
(en)
|
1999-04-16 |
2005-06-21 |
Novo Nordisk A/S |
Substituted imidazoles, their preparation and use
|
|
US6114350A
(en)
*
|
1999-04-19 |
2000-09-05 |
Nen Life Science Products, Inc. |
Cyanine dyes and synthesis methods thereof
|
|
US6610721B2
(en)
|
2000-03-17 |
2003-08-26 |
Novo Nordisk A/S |
Imidazo heterocyclic compounds
|
|
US6437147B1
(en)
|
2000-03-17 |
2002-08-20 |
Novo Nordisk |
Imidazole compounds
|
|
US6794405B2
(en)
|
2000-08-17 |
2004-09-21 |
Merck & Co., Inc. |
Alicyclic imidazoles as H3 agents
|
|
AU2001283573A1
(en)
*
|
2000-08-21 |
2002-03-04 |
Gliatech, Inc. |
The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
|
|
AU2002256967A1
(en)
*
|
2000-10-30 |
2002-09-12 |
Schering Corporation |
Treating or reducing the risk of cardiovascular disease
|
|
AU2003248584A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Warner-Lambert Company Llc |
Method of treating osteoarthritis
|
|
CA2555071A1
(en)
*
|
2004-02-02 |
2005-09-01 |
Pfizer Products Inc. |
Histamine-3 receptor modulators
|
|
WO2005082893A2
(en)
|
2004-02-25 |
2005-09-09 |
Eli Lilly And Company |
Histamine h3 receptor antagonists, preparation and therapeutic uses
|
|
MXPA06011167A
(es)
|
2004-04-01 |
2007-01-25 |
Eli Lilli And Company |
Agentes del receptor h3 de histamina, preparacion y usos terapeuticos.
|
|
US7696234B2
(en)
|
2004-06-02 |
2010-04-13 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
|
BRPI0514553A
(pt)
|
2004-08-23 |
2008-06-17 |
Lilly Co Eli |
composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
|
|
WO2006044228A1
(en)
|
2004-10-18 |
2006-04-27 |
Eli Lilly And Company |
Histamine h3 receptor inhibitors, preparation and therapeutic uses
|
|
CA2600757C
(en)
|
2005-03-17 |
2014-02-18 |
Eli Lilly And Company |
Pyrrolidine derivatives as histamine h3 receptor antagonists
|
|
EP1707203A1
(en)
|
2005-04-01 |
2006-10-04 |
Bioprojet |
Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
|
|
EP1868991B1
(en)
|
2005-04-01 |
2014-07-30 |
Eli Lilly And Company |
Histamine h3 receptor agents, preparation and therapeutic uses
|
|
EP1717235A3
(en)
|
2005-04-29 |
2007-02-28 |
Bioprojet |
Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
|
|
EP1717233A1
(en)
*
|
2005-04-29 |
2006-11-02 |
Bioprojet |
Histamine H3-receptor ligands and their therapeutic application
|
|
CA2622597A1
(en)
*
|
2005-09-15 |
2007-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Histamine h3 agonist for use as therapeutic agent for lipid/glucose metabolic disorder
|
|
EP1942104A1
(en)
*
|
2006-12-20 |
2008-07-09 |
sanofi-aventis |
Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
|
|
EP2389362B1
(en)
|
2009-01-21 |
2019-12-11 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
KR101736218B1
(ko)
|
2009-09-25 |
2017-05-16 |
오리존 지노믹스 에스.에이. |
라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
|
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
|
WO2011106573A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
BR122019020471B1
(pt)
*
|
2010-04-19 |
2021-06-22 |
Oryzon Genomics S.A. |
Inibidores da desmetilase específica para lisina 1, seus usos e método para sua identificação, e composições farmacêuticas
|
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
|
WO2012013728A1
(en)
|
2010-07-29 |
2012-02-02 |
Oryzon Genomics S.A. |
Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
|
|
WO2012045883A1
(en)
|
2010-10-08 |
2012-04-12 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
EP3981395A1
(en)
|
2011-02-08 |
2022-04-13 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
UA116765C2
(uk)
|
2011-10-20 |
2018-05-10 |
Орізон Джіномікс, С.А. |
(гетеро)арилциклопропіламіни як інгібітори lsd1
|
|
CN104203914B
(zh)
|
2011-10-20 |
2017-07-11 |
奥瑞泽恩基因组学股份有限公司 |
作为lsd1抑制剂的(杂)芳基环丙胺化合物
|
|
WO2013151982A1
(en)
|
2012-04-03 |
2013-10-10 |
Arena Pharmaceuticals, Inc. |
Methods and compounds useful in treating pruritus, and methods for identifying such compounds
|